Selling Buzz: Atara Biotherapeutics Inc. [ATRA] Chief Financial Officer Koppikar Utpal sells 2,485 shares of the company


The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Atara Biotherapeutics Inc. shares valued at $13,568 were sold by Koppikar Utpal on Feb 07. At $5.46 per share, Koppikar Utpal sold 2,485 shares. The insider’s holdings dropped to 188,849 shares worth approximately $0.68 million following the completion of this transaction.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Also, Touchon Pascal sold 15,591 shares, netting a total of over 70,004 in proceeds. Following the sale of shares at $4.49 each, the insider now holds 441,696 shares.

Before that, Koppikar Utpal had sold 6,255 shares from its account. In a trade valued at $28,086, the Chief Financial Officer traded Atara Biotherapeutics Inc. shares for $4.49 each. Upon closing the transaction, the insider’s holdings decreased to 6,255 shares, worth approximately $0.68 million.

As published in a research note from Citigroup on July 20, 2022, Atara Biotherapeutics Inc. [ATRA] has been rated down from a Neutral to a Sell and the price target has been revised to $3 from $8. This represents a -19.33% premium over Thursday’s closing price. Analysts at Stifel downgraded the stock from ‘”a Buy”‘ to ‘”a Hold”‘ outlook in a report released in mid July. As of July 13, 2022, JP Morgan has decreased its “an Overweight” rating to a “Neutral” for ATRA. Earlier on May 10, 2022, Citigroup downgraded its rating. Their new recommendation was “a Neutral” for ATRA stock which previously was a “a Buy”.

Analyzing ATRA Stock Performance

On Thursday, Atara Biotherapeutics Inc. [NASDAQ: ATRA] plunged -8.44% to $3.58. The stock’s lowest price that day was $3.57, but it reached a high of $3.80 in the same session. During the last five days, there has been a drop of approximately -16.16%. Over the course of the year, Atara Biotherapeutics Inc. shares have jumped approximately 9.15%. Shares of the company reached a 52-week high of $5.64 on 02/06/23 and a 52-week low of $3.22 on 01/04/23. A 50-day SMA is recorded $4.10, while a 200-day SMA reached $4.54. Nevertheless, trading volume fell to 0.99 million shares from 0.55 million shares the previous day.

Support And Resistance Levels for Atara Biotherapeutics Inc. (ATRA)

According to the 24-hour chart, there is a support level at 3.50, which, if violated, would cause prices to drop to 3.42. In the upper region, resistance lies at 3.73. The next price resistance is at 3.88. RSI (Relative Strength Index) is 35.80 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.37, which suggests the price will decrease in the coming days. Percent R is at 99.10%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.

Is Atara Biotherapeutics Inc. subject to short interest?

Stocks of Atara Biotherapeutics Inc. saw a sharp rise in short interest on Jan 30, 2023 jumping by 1.18 million shares to 14.19 million. Data from Yahoo Finance shows that the short interest on Dec 29, 2022 was 13.01 million shares. A jump of 8.32% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 12.91 of the overall float, the days-to-cover ratio (short ratio) jumped to 12.91.

Which companies own the most shares of Atara Biotherapeutics Inc. (ATRA)?

According to Wasatch Advisors, Inc. filings, the company currently owns 8,391,014 shares, which is about 8.84% of the total ATRA shares outstanding. The investor’s shares have appreciated by 254,651 from its previous 13-F filing of 8136363.0 shares. SSgA Funds Management, Inc. reduced a -5.53% interest valued at $38.78 million while BlackRock Fund Advisors purchased a 285,700 stake. A total of 604,539 shares of Atara Biotherapeutics Inc. were bought by The Vanguard Group, Inc. during the quarter, and -1,564,811 were sold by Maverick Capital Ltd. In its current portfolio, Redmile Group LLC holds 6,242,756 shares valued at $31.65 million.

In spite of this, 8 analysts ranked Atara Biotherapeutics Inc. stock as an Overweight at the end of 2023. On May 13, 2021, JP Morgan assigned a price target of “an Overweight” to the stock and upgraded coverage with a $29.


Please enter your comment!
Please enter your name here